Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -11.93 is 307% below its 5-year average of 5.77, near the high end of its 5-year range (-385.14–49.22).
As of the fiscal period ended Tuesday, June 30, 2026. 86.89% above its 12-month average of -91.02.
Reported quarterly debt to equity ratio; no daily interpolation.
DEBT TO EQUITY RATIO
-11.93
DEBT TO EQUITY RATIO AVG TTM
-91.02
DEBT TO EQUITY RATIO AVG 3Y
-0.23
DEBT TO EQUITY RATIO AVG 5Y
5.77
DEBT TO EQUITY RATIO AVG 10Y
2.22
DEBT TO EQUITY RATIO AVG 15Y
4.04
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+86.89%
CURRENT VS 3Y AVG
-5062.69%
CURRENT VS 5Y AVG
-306.84%
CURRENT VS 10Y AVG
-636.75%
CURRENT VS 15Y AVG
-395.31%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.69
median of 83 covered companies
CURRENT VS SECTOR MEDIAN
-1829.41%
vs the sector median at left
AbbVie Inc.
Market Cap
$439.68B
Debt to Equity Ratio
-11.93
TTM Avg
-91.02
3Y Avg
-0.23
5Y Avg
5.77
Market Cap
$366.74B
Debt to Equity Ratio
1.29
TTM Avg
0.90
3Y Avg
0.86
5Y Avg
0.95
Market Cap
$364.02B
Debt to Equity Ratio
0.74
TTM Avg
0.83
3Y Avg
0.79
5Y Avg
0.74
Market Cap
$344.67B
Debt to Equity Ratio
0.97
TTM Avg
1.06
3Y Avg
1.03
5Y Avg
0.98
Market Cap
$648.55B
Debt to Equity Ratio
0.58
TTM Avg
0.55
3Y Avg
0.51
5Y Avg
0.51
Market Cap
$224.09B
Debt to Equity Ratio
0.81
TTM Avg
0.70
3Y Avg
0.75
5Y Avg
0.76
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AbbVie Inc. (ABBV) | $439.68B | -11.93 | -91.02 | -0.23 | 5.77 |
| Merck & Co., Inc. (MRK)vs › | $366.74B | 1.29 | 0.90 | 0.86 | 0.95 |
| UnitedHealth Group Incorporated (UNH)vs › | $364.02B | 0.74 | 0.83 | 0.79 | 0.74 |
| Roche Holding AG (RHHBY)vs › | $344.67B | 0.97 | 1.06 | 1.03 | 0.98 |
| AstraZeneca PLC (AZN)vs › | $248.20B | 0.64 | 0.68 | 0.72 | 0.83 |
| Johnson & Johnson (JNJ)vs › | $648.55B | 0.58 | 0.55 | 0.51 | 0.51 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $224.09B | 0.81 | 0.70 | 0.75 | 0.76 |
| Amgen Inc. (AMGN)vs › | $212.20B | 4.90 | 8.27 | 9.39 | 7.67 |
| Novo Nordisk A/S (NVO)vs › | $200.54B | 0.63 | 0.70 | 0.49 | 0.42 |
| Abbott Laboratories (ABT)vs › | $182.59B | 0.64 | 0.30 | 0.38 | 0.44 |
Debt/Equity
-11.93
Current Ratio
0.81
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -11.93 |
| 2026-03-31 | -10.95 |
| 2025-12-31 | -21.06 |
| 2025-09-30 | -26.02 |
| 2025-06-30 | -385.14 |
| 2025-03-31 | 49.22 |
| 2024-12-31 | 20.40 |
| 2024-09-30 | 11.78 |
| 2024-06-30 | 10.42 |
| 2024-03-31 | 9.24 |
| 2023-12-31 | 5.80 |
| 2023-09-30 | 5.02 |
| 2023-06-30 | 4.74 |
| 2023-03-31 | 4.68 |
| 2022-12-31 | 3.72 |
| 2022-09-30 | 4.35 |
| 2022-06-30 | 4.98 |
| 2022-03-31 | 4.51 |
| 2021-12-31 | 5.03 |
| 2021-09-30 | 5.96 |
| 2021-06-30 | 6.53 |
| 2021-03-31 | 6.24 |
| 2020-12-31 | 6.66 |
| 2020-09-30 | 5.70 |
| 2020-06-30 | 5.94 |
| 2020-03-31 | -9.04 |
| 2019-12-31 | -8.21 |
| 2019-09-30 | -4.71 |
| 2019-06-30 | -4.40 |
| 2019-03-31 | -4.80 |
| 2018-12-31 | -4.77 |
| 2018-09-30 | -13.87 |
| 2018-06-30 | -11.00 |
| 2018-03-31 | 10.49 |
| 2017-12-31 | 7.33 |
| 2017-09-30 | 5.65 |
| 2017-06-30 | 6.20 |
| 2017-03-31 | 7.39 |
| 2016-12-31 | 7.95 |
| 2016-09-30 | 5.77 |
| 2016-06-30 | 6.71 |
| 2016-03-31 | 6.87 |
| 2015-12-31 | 8.03 |
| 2015-09-30 | 6.61 |
| 2015-06-30 | 5.65 |
| 2015-03-31 | 11.09 |
| 2014-12-31 | 8.60 |
| 2014-09-30 | 3.18 |
| 2014-06-30 | 2.83 |
| 2014-03-31 | 3.07 |
| 2013-12-31 | 3.28 |
| 2013-09-30 | 4.14 |
| 2013-06-30 | 4.15 |
| 2013-03-31 | 5.09 |
| 2012-12-31 | 4.66 |
| 2012-09-30 | 0.00 |
| 2012-06-30 | 0.00 |
| 2012-03-31 | 0.00 |
| 2011-12-31 | 0.00 |
| 2011-09-30 | 0.00 |
| 2011-06-30 | 0.00 |
| 2011-03-31 | 0.00 |
